Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

ABSTRACT:

Purpose

Local ablative treatment to oligometastatic patients can result in long-term disease-free survival in some cancer patients. The importance of this treatment paradigm in prostate cancer is a rapidly evolving field. Herein, we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative stereotactic ablative radiation (SABR).

Methods

Records of men with OPC who underwent consolidative SABR at our institution were reviewed. SABR was delivered in 1-5 fractions of 5-18 Gray. Kaplan-Meier estimates of local progression-free survival (LPFS), biochemical progression-free survival (bPFS; PSA nadir + 2), distant progression-free survival (DPFS), and time-to-next intervention (TTNI) were c

SUBMITTER: Moyer CL 

PROVIDER: S-EPMC6401357 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature